目的探索微创治疗与DC-CIK细胞治疗肝癌原发性肝癌患者24例确诊病例治疗的临床应用价值。方法对确诊为原发性肝癌患者24例进行TACE,术后1个月,行冷冻消融,术后一个半月应用DC-CIK治疗。结果患者半年生存率为91.67%。1年生存率91.67%。经TACE治疗后ALT、AST、Tbil在术后显著性上升,AFP水平显著性下降,CT下坏死病灶内可见碘油沉积,24例患者无完全坏死病例。经氩氦刀治疗后肝功能无统计学差异变化,AFP水平下降,CT表现20例肿瘤完全坏死,4例肿瘤残存,经免疫细胞治疗后ALT、AST、TBil均明显降低,治疗后AFP明显减低,CT下2例患者肿物明显增大,2例患者维持稳定,20例患者肿瘤完全坏死。结论 DC-CIK细胞治疗联合微创介入治疗原发性肝癌可提高患者的生存率,可有效的降低AFP的水平。 Objective To explore the clinical value of minimally invasive treatment and DC-CIK cell therapy in the treatment of 24 patients with primary liver cancer with hepatocellular carcinoma. Methods TACE was performed in 24 patients diagnosed as primary hepatocellular carcinoma (HCC). One month after operation, they were treated by cryoablation and DC-CIK one and a half months after operation. Results The half-year survival rate was 91.67%. 1-year survival rate of 91.67%. After TACE treatment, ALT, AST, Tbil significantly increased after operation, AFP levels decreased significantly, necrosis of the lesion visible CT lipiodol deposition, 24 patients without complete necrosis. There was no significant difference in liver function after treatment with argon-helium knife. The AFP level was decreased. CT showed complete necrosis in 20 cases and residual tumor in 4 cases. The levels of ALT, AST and TBil decreased significantly after treatment with immune cells, and AFP decreased significantly , 2 cases of patients with CT significantly increased the mass, 2 patients remained stable, 20 patients with complete tumor necrosis. Conclusion DC-CIK cell therapy combined with minimally invasive interventional treatment of primary liver cancer can improve the survival rate of patients, which can effectively reduce the level of AFP.